|
Active substance |
Crizotinib |
|
Holder |
Pfizer |
|
Status |
Closed |
|
Indication |
ROS1-positive non-small cell lung cancer (NSCLC) |
|
Public documents |
|
|
Last update |
12/07/2018 |
Xalkori®
Last updated on 10/09/2024